SECONDARY PREVENTIONS Jaimon Stucki MS-1 PSCOM. Blood Draw.

Slides:



Advertisements
Similar presentations
Agents Used in the Treatment of Hyperlipidemia
Advertisements

Treat Everyone to an LDL-C of 70mg/dl? Daniel Edmundowicz, MS, MD, FACC Associate Professor Of Medicine Director, Preventive Cardiology UPMC Cardiovascular.
New Approaches to LDL Reduction Cholesterol Absorption Inhibitors.
The importance of lipid lowering through liver and intestine: An overview of all relevant data for atherosclerosis Prof. Alberto Corsini University of.
Lipid Disorders and Management in Diabetes
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Pathway of Exogenous Cholesterol Metabolism
CHOLESTEROL LOWERING.
Drugs and Dyslipidemias (statins and other lipid and atherosclerosis-modifying drugs) October 18, 2006 Frank F. Vincenzi.
Diagnosis and Treatment of Dyslipidemia  New guidelines are based on the “Adult Treatment Plan III (ATP III)” 2004  Focus = multiple risk factor assessment.
Dyslipidemia/Lipid management in Diabetes. M ECHANISMS R ELATING I NSULIN R ESISTANCE AND D YSLIPIDEMIA  TG  Apo B  VLDL (hepatic lipase) Kidney (CETP)CEHDL.
How Aggressive do we get on Lipids? Christopher Cannon, M.D. Senior Investigator, TIMI Study Group Cardiovascular Division, Brigham and Women’s Hospital,
Anti-Hypercholesterolemic Agents  Biosynthesis and Metabolism of Cholesterol  What is arteriosclerosis? - Link between arteriosclerosis and cholesterol.
Drug List Protonix pantoprazole Proton Pump Inhibitor GERD / Ulcers.
Cholesterol Metabolism
The Science of Plant Stanol Ester. Contents Background Plant stanol ester and LDL-cholesterol lowering Dose-response of plant stanol ester with high daily.
An Academic Research Organization of Brigham and Women’s Hospital and Harvard Medical School LAPLACE-TIMI 57 Primary Results A Double-blind, Randomized,
ANTILIPEMICS LILLEY, READING & WORKBOOK: CHAP 28 Cardiovascular System.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.
Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
Role of Rosuvastatin in the Treatment of Dyslipidemia
1 LDL-C and CV Risk: What We Know and Don't Know Joseph J. Saseen, PharmD, FCCP, BCPS, CLS Associate Professor Clinical Pharmacy and Family Medicine University.
The Antihyperlipidemic Medications l Classifications of Lipoproteins – Chylomicrons l Formed in the mucosal cells of the gut l Protein coated dietary lipids.
Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study I. Migdalis a, A. Efthimiadis b, St. Pappas c, D. Alexopoulos.
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 1 CHAPTER 29 Hypolipidemic Drugs.
Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium sized arteries.
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.
Dyslipidemia: What Every Resident Should Know
Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.
Slide 1 Downloaded from Ezetimibe Factorial Coadministration Studies.
Slide 1 EZT 2003-W SS Mechanism of Action and Pharmacology of Ezetimibe Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
Pharmacoeconomics and Outcomes Research Dean G. Smith, Ph.D. October 10, 2005 UM Student Chapter.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Step 3 P-treatment: Drug Class Selection. Pharmacological and Non- Pharmacological Management Dyslipidemia drug therapyLifestyle modification Smoking.
Chapter 19 Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
HYPERLIPIDEMIA Applied Therapeutics Dr. Riyadh Mustafa Al-Salih.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 28 Antilipemic Drugs.
Copyright® Raisio Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced.
The IDEAL Cholesterol Christopher Cannon, M.D. TIMI Study Group Brigham and Women’s Hospital Cannon CP. JAMA 2005;294:
EZT 2003-W SSSlide 1 Cholesterol From Two Sources Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
Chemical Structure of Rosuvastatin Relative lipophilicity * Rosuvastatin Cerivastatin Simvastatin Fluvastatin Atorvastatin Pravastatin.
Ezetimibe Overall Conclusions
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal low-density lipoprotein is 50 to 70 mg/dl:
Overview Lipoprotein metabolism Digestive lipid metabolism
Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome
Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.
Atorvastatin Calcium Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of.
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,
Drugs for Lipid Disorders
Anti-Hypercholesterolemic Agents
By: Dr Israa Omar MBBS, MRCP, MSc pharmacology
Formative Test.
Anti-Hypercholesterolemic Agents
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
Cardiovascular System
Evaluating LDL-C Recommendations
New LDL-C Lipid Targets
Updates in Cardiovascular Medicine
Major classes of drugs to reduce lipids
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Section 6: Update on lipid treatment guidelines
Presentation transcript:

SECONDARY PREVENTIONS Jaimon Stucki MS-1 PSCOM

Blood Draw

Centrifuge

Lipid Profile  Triglycerides  LDL Cholesterol  HDL Cholesterol  Total Cholesterol  Chol/HDL

Where does cholesterol come from?

Deep Fried Twinkie

Cholesterol Levels Are Affected by Multiple Organ Systems Net Cholesterol Balance in Humans LDL Receptors Cholesterol Synthesis LDL and Other Receptors IDL-C = intermediate-density lipoprotein cholesterol; VLDL-C = very low-density lipoprotein cholesterol. Turley SD et al. Prev Cardiol. 2003;6:29–33, 64; Dietschy JM. Am J Clin Nutr. 1997;65(suppl): 1581S–1589S, adapted with permission by the American Journal of Clinical Nutrition. © Am J Clin Nutr. American Society for Clinical Nutrition. Cholesterol Synthesis Synthesized Cholesterol ≈50% of Intestinal Cholesterol Is Absorbed Transport via HDL-C and LDL-C (≈75%) Chylomicron Transport Biliary Cholesterol Transport Fecal Sterols Dietary Cholesterol (≈25%) Extrahepatic Organs LiverIntestine LDL-C IDL-CVLDL-C

 Fenofibrate (Tricor)  Lower serum Triglycerides  Niaspan  Increase HDL  Flushing/Slow-Release FibratesNiacin

Statins  HMG CoA Reductase Inhibitors  Atorvastatin,Lovastatin, Rosuvastatin, Simvastatin (Zocor)  Decrease LDL levels

Cholesterol Levels Are Affected by Multiple Organ Systems Net Cholesterol Balance in Humans LDL Receptors Cholesterol Synthesis LDL and Other Receptors IDL-C = intermediate-density lipoprotein cholesterol; VLDL-C = very low-density lipoprotein cholesterol. Turley SD et al. Prev Cardiol. 2003;6:29–33, 64; Dietschy JM. Am J Clin Nutr. 1997;65(suppl): 1581S–1589S, adapted with permission by the American Journal of Clinical Nutrition. © Am J Clin Nutr. American Society for Clinical Nutrition. Cholesterol Synthesis Synthesized Cholesterol ≈50% of Intestinal Cholesterol Is Absorbed Transport via HDL-C and LDL-C (≈75%) Chylomicron Transport Biliary Cholesterol Transport Fecal Sterols Dietary Cholesterol (≈25%) Extrahepatic Organs LiverIntestine LDL-C IDL-CVLDL-C

The Statin Decade: For LDL: “Lower is Better” R² = p < LDL Cholesterol (mg/dl) CHD Events (%) Adapted and Updated from O’Keefe, J. et al., J Am Coll Cardiol 2004;43: S CARE LIPID HPS PROVE IT –TIMI 22 TNT

Cholesterol Levels Are Affected by Multiple Organ Systems Net Cholesterol Balance in Humans LDL Receptors Cholesterol Synthesis LDL and Other Receptors IDL-C = intermediate-density lipoprotein cholesterol; VLDL-C = very low-density lipoprotein cholesterol. Turley SD et al. Prev Cardiol. 2003;6:29–33, 64; Dietschy JM. Am J Clin Nutr. 1997;65(suppl): 1581S–1589S, adapted with permission by the American Journal of Clinical Nutrition. © Am J Clin Nutr. American Society for Clinical Nutrition. Cholesterol Synthesis Synthesized Cholesterol ≈50% of Intestinal Cholesterol Is Absorbed Transport via HDL-C and LDL-C (≈75%) Chylomicron Transport Biliary Cholesterol Transport Fecal Sterols Dietary Cholesterol (≈25%) Extrahepatic Organs LiverIntestine LDL-C IDL-CVLDL-C

Ezetimibe l Blocks a specific receptor in small intestine: reduces absorption of dietary and biliary cholesterol by 50% l Well tolerated

Clinical Studies with Ezetimibe Monotherapy *P  0.01 vs placebo. Pooled Results From 2 Multicenter, Double-Blind, Placebo-Controlled, 12-Week Studies in 1,719 Patients With Primary Hypercholesterolemia Source: Ezetimibe package insert

The Statin Decade: For LDL: “Lower is Better” R² = p < LDL Cholesterol (mg/dl) CHD Events (%) Adapted and Updated from O’Keefe, J. et al., J Am Coll Cardiol 2004;43: S CARE LIPID HPS PROVE IT –TIMI 22 TNT

Simva + EZ Vytorin

The Statin Decade: For LDL: “Lower is Better” R² = p < LDL Cholesterol (mg/dl) CHD Events (%) Adapted and Updated from O’Keefe, J. et al., J Am Coll Cardiol 2004;43: S CARE LIPID HPS PROVE IT –TIMI 22 IMPROVE IT TNT

“Is (Even) Lower (Even) Better ?” Can Eze/Simva lower LDL to a greater degree than standard treatment (Simva 40 mg) and by doing so reduce major cardiovascular events?

Eze/Simva Surrogate and Clinical Outcome ProgramTrialPopulationEndpointTreatment ENHANCEHeFH (n = 720) Carotid IMT Eze/Simva 10/80 vs Simva 80 IMPROVE-ITACS (n = 10,000) MACE Eze/Simva 10/40 vs Simva 40

Drug Cost  Fenofibrate 200mg$69/30 day  Lovastatin 40mg$36/30 day  Atorvastatin 20mg (Lipitor)$120/30 day  Simvastatin 40mg (Generic)$28/30 day  Ezetimibe 10mg (Zetia)$100/30 day  Vytorin 40/10mg$108/30 day